ESMO Congress 2019
Are we reaching a turning point in metastatic prostate cancer?
PROfound study shows benefit in radiological progression-free survival with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant prostate cancer
Updated results from the BEACON trial show unprecedented overall survival in the second-line treatment of CRC
Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer
Off-label therapies: what is their future?
Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge
ClarIDHy trial reports a small improvement in progression-free survival
Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy
Chemotherapy plus endocrine therapy increases long-term recurrence-free survival in women with high-risk HR+ breast cancer
Results from TAILORx trial presented at ESMO 2019
Targeting HER2 amplifications in metastatic colorectal cancer: searching for the most active combination therapy?
Mixed results from the the HERACLES-B, TRIUMPH and MOUNTAINEER trials
Closing the clinician–patient gap with patient-reported outcomes
PROs encourage patient-centred cancer care